» Articles » PMID: 22387083

A Combined Strategy Improves the Solubility of Aggregation-prone Single-chain Variable Fragment Antibodies

Overview
Specialty Molecular Biology
Date 2012 Mar 6
PMID 22387083
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Recombinant single-chain variable fragment (scFv) antibodies have wide applications in the areas of biotechnology and medicine. However, there is currently no universal expression-purification system for generating different soluble scFvs. In this study, A15 and E34, two genes coding scFvs against human IL-17A, were fused with N-terminal signal peptide sequences pelB or STII, or with highly hydrophilic tags Trx, NusA, or MBP, respectively. These constructs were expressed in Escherichia coli. We found that the scFvs fused with either NusA or MBP showed a higher solubility than fused with signal peptides or Trx. The scFvs were aggregated when the NusA or MBP was removed by thrombin. Interestingly, we observed a reduction of precipitation when the fusion proteins were expressed in Origami B(DE3)pLysS cells but not in BL21(DE3)pLysS. Because cleaving the tags resulted in the aggregation of scFvs, several solubility-enhancing additives were added in the digestion buffer and only L-arginine (Arg) or Tween20 promoted the solubility. After an affinity chromatography, the scFvs were separated from the tags with the purity up to 90%. The final yield of scFvs from the scFv-MBP system was approximately 8.9 mg/L of culture medium and 1.5 mg/g of wet weight cells, which was 1.6-fold higher than the yield from the scFv-NusA system. The obtained scFvs exhibited normal binding affinities and activities after endotoxin removal. In conclusion, we describe a strategy combining the fusion tags, the Escherichia coli with oxidizing bacterial cytoplasm, and the solubility-enhancing additives for expressing and purifying the soluble and functional scFvs.

Citing Articles

CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.

Ercilla-Rodriguez P, Sanchez-Diez M, Alegria-Aravena N, Quiroz-Troncoso J, Gavira-ONeill C, Gonzalez-Martos R Front Immunol. 2024; 15:1333150.

PMID: 39091493 PMC: 11291200. DOI: 10.3389/fimmu.2024.1333150.


Selection and characterization of human scFvs targeting the SARS-CoV-2 nucleocapsid protein isolated from antibody libraries of COVID-19 patients.

Lisi S, Malerba F, Quaranta P, Florio R, Vitaloni O, Monaca E Sci Rep. 2024; 14(1):15864.

PMID: 38982108 PMC: 11233501. DOI: 10.1038/s41598-024-66558-0.


Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin.

Zheng L, Wang H, Zhou J, Shi G, Ma J, Jiang Y J Immunother Cancer. 2024; 12(7).

PMID: 38964787 PMC: 11227840. DOI: 10.1136/jitc-2024-008888.


Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.

Ku K, Tang J, Chen Y, Shi Y Int J Mol Sci. 2024; 25(10).

PMID: 38791398 PMC: 11120994. DOI: 10.3390/ijms25105361.


Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.

Lin K, Xia B, Wang X, He X, Zhou M, Lin Y J Transl Med. 2024; 22(1):349.

PMID: 38610029 PMC: 11015683. DOI: 10.1186/s12967-024-05159-x.